(PCA) directed against the proton pump (H+/ K+ ATPase) (1) . The autoimmune attack to the parietal cells results in decreased acid secretion and hypergastrinemia (1) . Hypergastrinemia promotes the growth of the ECL cells of the oxyntic mucosa so that diffusion to micronodular ECL cell hyperplasia develops and, after a latent period of many years, carcinoid and multiple ECL tumors in 10% of the cases (2, 3) . Hyperplasia of gastrin-producing cells in both the antrum and proximal duodenum, can progress to formation of a gastrin-producing cell nodule (4) . Nowadays, AIG is listed as a precancerous condition (2) . The association of AIG with autoimmune thyroid diseases (AlTO) is well known, but its prevalence varies widely in literature reports, depending on the type of patient studied, the diagnostic accuracy and the immunological methods used for the detection of AIG-associated autoantibodies (5) (6) (7) . The prevalence of serum PCA in AlTO was estimated to vary between 24 and 29%, being slightly higher in Graves' disease patients than in HT patients (1, 8) . Gastric endocrine cancers (EC) are considered rare, underdiagnosed tumors, that account for approximately for 0.1-0.6 % of all carcinomas of the stomach, and frequently metastasize to lymph nodes and the liver even in the early stages of the disease, therefore early detection and therapeutic effort are essential for improving the prognosis (9, 10) . The main purpose ofthis study was to define the prevalence of AIG, hypergastrinemia and the presence of ECL hyperplasia in HT. We also evaluated the efficacy of treatment with a somatostatin analogue in HT with ECL hyperplasia.
MATERIALS AND METHODS

Patients
The study was carried out from January 2009 to December 2011. Over a period of 24 months, 146 Hashimoto's thyroiditis (HT) patients (121 female, 25 male, aged 16-70 years) referred to the Endocrinology Unit of the Second University of Naples, Medical Center, were enrolled in a prospective study. Subjects who were positive for anti-thyroid peroxidase and anti-thyroglobulin antibodies and who had thyroid parenchyma heterogeneity with reduced echogenicity were considered as HT and were included in the study. Ongoing or previous (i.e. within three months) proton pump therapy was considered exclusion criteria. A baseline visit was made in which personal data, past medical history, and symptoms were collected. All cases underwent the following study protocol to assess thyroid function, anti-thyroid antibodies, serum gastrin, and chromogranin A (CgA) levels. HT with subclinical hypothyroidism (72 subjects) and with hypothyroidism (20 subjects) was treated by replacement thyroxin. To exclude possible interference, only HT with gastrin and CgA significantly higher than normal (cut off were > 250 pg/ml and >80 ng/ml, respectively) underwent anti-gastric parietal cell antibody assay (PCA) and gastro esophageal endoscopy (EGDS) with multiple biopsies in the gastric antrum, angulus, body, and visible lesions. H. pylori infection was assessed by rapid urease test (RUT) and histology and patients were considered to be infected if both tests were positive. Gastritis was graded according to the modified Sydney system (II). Furthermore, the degree of endocrine cell proliferation (linear, micro nodular and adenomatous hyperplasia, dysplasia) and the presence of endocrine tumors at immunohistochemistry were assessed through the evaluation of CgA positive cells (12) .
All patients who had neuroendocrine cells hyperplasia or endocrine tumor of the stomach associated with AIG and HT underwent somatostatin receptor scintigraphy with lllin-diethylenetriaminepenta acetic acid-octreotide (Octreoscan), and were then treated with long acting, repeatable somatostatin analogue (Octreotide LAR, Novartis AG, Basel) at a dose of 30 mg intramuscularly every 28 days. All patients received 13 injections. The flow chart of the study protocol is shown in Fig. I . Patients were evaluated before therapy and at followup, scheduled at 3-and 6-month intervals for 12 months. After 3 and 6 months and again after 12 months, plasma CgA levels (normal value < 80 ng/ml CIS BIO CGA RIA KIT, CIS BIO, Milan, Italy) and serum gastrin levels (reference value 0 -80 pg/ml with Immulite 2000 Gastrin -PIL2KGA-I0, 2006-I2-29-Siemens Medical Solutions Diagnostics, L.A., CA, USA) were detected. After 12 months EDGS was performed with multiple biopsies in the antrum, body, fundus, and the lesions. The review committee of the Second University of Naples approved the study protocol and all patients gave written informed consent.
Statistical analysis
The descriptive statistics used were mean, S.E.M., and frequencies. The data of CgA and gastrin were analyzed by the Wilcoxon test. P values < 0.05 were considered statistically significant. The Wilson score method without continuity correction was used to calculate a confidence interval for a proportion. The confidence interval for the diagnostic odds ratio was calculated as described (13) . The analyses were carried out using the SPSS version 15.0 for Windows XP.
RESULTS
Hypergastrinemia andgastric Eerisk in Hashimoto s thyroiditis patients with autoimmune gastritis
From an initial total of 146 enrolled patients, 115 patients (20 men -95 women, age range 16-70 years) completed the study. The clinical characterization of the study subjects is shown in Table I . Twenty-one per cent (24 out of 115) ofHT patients were PCA positive (the estimated population proportion is 0.2087: CI: O. 2082 to 0.2091, estimated population odds ratio are 0.2637 CI: O. 2630 to 0.2645), 7 ofwhom had normal gastrin serum level and 17 hypergastrinemia (Fig 2) . Gastrin and CgA were found significantly higher than normal levels (552.6±250 pg/ml; 288±152.3 ng/ml respectively) in 17 patients (14.7%) (The estimated population proportion is 14.7; CI 0.1474 to 0.148, estimated odds ratio 0.1735, CI 0.1729 to 0.1740) ( Fig 2) . All of the 17 patients had been complaining of indeterminate dyspepsia (i.e. ulcerlike and dismotility-like symptoms). All of the PCA positive patients underwent EGDS with multiple biopsies in the antrum, angulus, body, and visible lesions. Histology showed chronic gastritis, corpus prevalent, and atrophic gastritis of the body/fundus in all of the 17 patients with hypergastrinemia and increased CgA levels (Table I) (Fig. 2) . The remaining seven patients with isolated PCA positivity had only moderate chronic gastritis, body prevalent, without atrophy. Moreover, diffused hyperplasia of the entero-chromaffin-like cells (ECL) of the body was found in 3/17 HT patients with hypergastrinemia and increased CgA levels (the estimated population proportion is 0.0261: CI 0.2737 to 0.3514; odds ratio 0.0268 CI: 0.3769 to 0.5418), one of whom also had a 6 mm non-polypoid lesion in the gastric body that, at histology, was a type 1 gastric carcinoid (Fig. 2) . None of them had H. pylori infection as assessed by rapid urease test and histology. Interestingly, the level ofTSH was statistically higher (p<O.OO 1) in the patients with hypergastrinemia than in those who had gastrin levels < 250 pg/ml (Table I) .
Hashimoto sthyroiditis patients with AIG and enterochromaffin-like cells hyperplasia, and somatostatin analogs treatment results
The three HT patients with AIG and ECL hyperplasia, including the one with type-l carcinoid, underwent an Octreoscan, which resulted negative in all cases. Moreover, these patients were treated with Octreotide LAR 30 mg/28 days. Octreotide LAR therapy was well tolerated by all patients. All of these patients had been complaining ofindeterminate dyspepsia (i.e. ulcer-like and dismotility-like symptoms). Soon after initiation of therapy, patients showed a marked improvement ofclinical symptoms. The clinical features and procedures in the three HT patients with ECL hyperplasia are shown in Table  II . All patients completed 13 injections of Octreotide LAR 30 mg. After 3 months of treatment, gastrin and CgA levels were significantly reduced (p<O.OI) and their levels remained significantly lower than baseline during 12 months of therapy ( Fig. 3) . Patients continued to remain free of symptoms until end of follow-up. After one year, they showed normal gastrin and CgA values and EGDS detected absence of ECL hyperplasia (data not shown), while the type-l carcinoid was unmodified. hypergastrinemia and AIG, being at higher risk to develop gastric cancer than control population (5, 9) . Our study shows that AIG as assessed by hypergastrinemia, PCA positivity and histology, was present in 14.7% of subjects in a series of 115 patients with HT, three of whom (2.6%) also had ECL hyperplasia, one with type-I carcinoid.
DISCUSSION
Our report calls attention to the HT patients with
Finally, treatment with a somatostatin analogue caused the regression of ECL hyperplasia in all of the treated patients. Our results indicate that AIG could be misdiagnosed in HT patients, by using PCA positivity only. Plasma gastrin and CgA serum level assays could be useful tools in selecting HT patients, in particular when they complain of indeterminate dyspepsia, to submit to gastroscopy. In fact, isolated PCA does not seem to be relevant to diagnose AIG and, in support of this assumption, we did not find any histologic alteration in any of the 7 patients with isolated PCA positivity. The prevalence of 14.7% of AIG in HT patients found in this study was lower than that reported in other studies (i.e. 24-29%) (I, 8) . This apparent discrepancy might be attributed to variable accuracy of diagnostic methods. In some studies, diagnosis of AIG was based only on the positivity of PCA (1, 8) . We performed EGOS only on selected HT patients with hypergastrinemia, increased CgA serum levels, and PCA positivity.
To address the potential negative impact of overdiagnosis and over-investigation, our data indicate that an accurate selection of HT patients is needed to identify subjects undergoing determination of PCA, gastrin, CgA serum levels and EGOS, in order to identify AIG and ECL hyperplasia. Gastric endocrine carcinoma (EC) is an uncommon tumor, accounting for 0.1-0.6% ofgastric carcinomas (14) . EC exhibits specific epidemiologic profiles with different patterns of incidence, age at diagnosis, stage and survival, which require specific classification and risk stratification for a better clinical management (9, 15) . AIG represents a definite risk factor for gastric EC, in particular when associated with ECL hyperplasia, and, therefore, an early diagnosis may be relevant as to the prevention of EC (16) . Therefore, in this study we looked for association between HT, one of the commonest autoimmune disorders affecting approximately 5% of the population, and EeL hyperplasia. To date, no data regarding HT and ECL hyperplasia were found in the literature using the PubMed database, and we found that 2.6% of HT patients presented ECL hyperplasia of the gastric mucosa. A recent review of the literature shows no data on the correlation between neuroendocrine cancer development and thyroid disorders (17) . Dogan et al. showed in a retrospective analysis of seventy-one patients with neuroendocrine tumor synchronous goiter/thyroiditis in 17.8% of the patients. Our finding adds new information on the possible correlation between gastric EC risk development and thyroid disorders. Given the potential risk to develop gastric EC, our data point out the relevance of an early diagnosis and treatment of AIG-associated ECL hyperplasia in selected HT patients (18) . This is supported by the fact that all of the three patients with AIG and ECL hyperplasia responded to treatment with a somatostatin analogue and at one year follow-up were free ofECL hyperplasia.
The current gold standard for functional imaging of neuroendocrine tumors is somatostatin receptor scintigraphy with III Indiethylenetriaminepentaacetic acid-octreotide (i.e. Octreoscan) targeting the somatostatin receptors with the highest affinity for subtype 2. Our data showed that Ocreoscan was not useful in detecting pre-neoplastic gastric EC lesions. Therefore, in the case of ECL hyperplasia of gastric mucosa, the finding of negative radio labelled uptake by somatostatin receptor scintigraphy is not indicative for somatostatin analogue treatment and/or outcome. This might be due to the expression pattern of the various subtypes of receptors and their density on the cell surface, which differs among the various neuroendocrine tumors. In particular, in preneoplastic cells, receptor density might still be too low to be detected even in the patient with type-l carcinoid, probably due to the small size ofthe lesion (i.e. < Iern).
To date, no data are available regarding the use of somatostatin analogues for prevention of gastric EC in patients with ECL hyperplasia (9) . Nevertheless, surveillance is recommended in the presence of ECL hyperplasia and AIG, considered a pre-neoplastic lesion (9) . In our study, we observed regression of ECL hyperplasia following treatment with a somatostatin analogue in three HT patients. This is in agreement with the report by Khuro et al. who showed regression of neoplastic lesion in three patients with type-I gastric neuroendocrine tumors following long-term treatment with somatostatin analogues (19) . Moreover, another study showed that nine patients with more than five type-I gastric endocrine tumors, without invasion of the muscularis propria, treated with long-acting somatostatin analogues for 12 months presented a significant reduction of CgA and gastrin levels at 6 and at 12 months and disappearance of gastric neoplastic lesions after 12 months of therapy (20) . In our study, we had only one patient with a type-I carcinoid and there was no significant regression of the neoplastic lesion after 1 year of treatment with a somatostatin analogue.
TSH levels were significantly higher in the 17 HT patients with hypergastrinemia and ECL hyperplasia than in those with gastrin levels < 250 pg/ml. We may only speculate that genetic and! or environmental factors linked to severe HT, may somehow also predispose to a higher risk of developing hypergastrinemia and ECL lesions in the stomach.
The main message is that HT patients with hypergastrinemia, AIG, and ECL hyperplasia may need a more accurate surveillance for early signs of pre-neoplastic lesions leading to gastric EC development. Considering our results, we suggest restricting the determination of PCA, gastrin and CgA serum levels only to selected HT patients, with a particular attention to individuals complaining of dyspepsia, in order to limit a high cost intervention. The benefit of this intervention could be the early diagnosis of AIG and EC hyperplasia. The complete remission of hypergastrinemia and (pre) neoplastic gastric EC after one year of somatostatin analogue therapy, supports our assumption, confirms previous reports, and adds new information on the ability of somatostatin analogs not only to cure but also to prevent tumors. Nevertheless, our results might need to be supported by more data and we suggest caution against our assumptions.
